Compare AIRS & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRS | ACOG |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 193.6M |
| IPO Year | 2021 | 2024 |
| Metric | AIRS | ACOG |
|---|---|---|
| Price | $1.76 | $8.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 825.3K | 89.3K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $151,818,000.00 | $10,220,275.00 |
| Revenue This Year | N/A | $152.34 |
| Revenue Next Year | $2.65 | $91.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $4.50 |
| 52 Week High | $12.00 | $10.14 |
| Indicator | AIRS | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 28.28 | 56.15 |
| Support Level | $1.51 | $5.49 |
| Resistance Level | $3.31 | $9.95 |
| Average True Range (ATR) | 0.16 | 0.47 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 93.62 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.